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STATEMENT OF TRANSLATIONAL RELEVANCE: 67
68
The strategy of combining endocrine therapy with PI3K-mTOR inhibition has shown 69
promise in oestrogen receptor-positive breast cancer, but new agents and combinations 70
with a better therapeutic index are urgently needed. Taselisib is a potent, selective, 71
PI3kinase inhibitor. In this phase 1b trial, 30 patients with ER-positive, metastatic breast 72
cancer who had failed prior endocrine therapy were treated with escalating doses of 73
taselisib combined with tamoxifen. The combination was generally well tolerated, with 74
adverse events as expected for this class of drugs, including diarrhea, mucositis and 75
hyperglycemia. No dose-limiting toxicities were observed. Objective responses were seen 76
in 6 out of 25 patients with RECIST-measurable disease (ORR 24%). 12 out of 30 patients 77
(40%) had disease control for 6 months or more. Circulating tumor DNA studies using 78
next-generation tagged amplicon sequencing identified early indications of treatment 79
response and mechanistically-relevant correlates of clinical drug resistance (eg. mutations 80
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ABSTRACT: 84
85
Background: The strategy of combining endocrine therapy with PI3K-mTOR inhibition has86
shown promise in oestrogen-receptor (ER)-positive breast cancer, but new agents and 87
combinations with a better therapeutic index are urgently needed. Taselisib is a potent, 88
selective, beta-isoform sparing PI3 kinase inhibitor. Patients and Methods: 30 patients 89
with ER-positive, metastatic breast cancer who had failed prior endocrine therapy were 90
treated with escalating doses of taselisib (2 or 4 mg in an intermittent or continuous 91
schedule) combined with tamoxifen 20mg once daily in this phase 1b study using a ‘rolling 92
six’ design. Results: Taselisib combined with tamoxifen was generally well tolerated, with 93
treatment-emergent adverse events as expected for this class of drugs, including diarrhea94
(13 patients, 43%), mucositis (10 patients, 33%) and hyperglycemia (8 patients, 27%). No95
dose-limiting toxicities were observed. Objective responses were seen in 6 out of 25 96
patients with RECIST-measurable disease (ORR 24%). Median time to disease 97
progression was 3.7 months. 12 out of 30 patients (40%) had disease control for 6 months 98
or more. Circulating tumor (ct)DNA studies using next-generation tagged amplicon 99
sequencing identified early indications of treatment response and mechanistically-relevant100
correlates of clinical drug resistance (eg. mutations in KRAS, ERBB2) in some patients.101
Conclusions: Taselisib can be safely combined with tamoxifen at the recommended 102
phase 2 dose of 4mg given once daily on a continuous schedule. Preliminary evidence of 103
anti-tumor activity was seen in both PIK3CA mutant and wild-type cancers. The104
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INTRODUCTION 108
109
The strategy of combining endocrine therapy with inhibitors of the phosphatidylinositol 3–110
kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway has shown promise 111
in ER-positive breast cancer(1,2), where there is a high prevalence of pathway alterations.112
However the modest improvement in treatment efficacy when adding these agents has 113
frequently been offset by significant increased toxicity(3).114
115
Taselisib (GDC-0032) is an oral, potent, isoform-selective inhibitor of PI3K alpha, delta and 116
gamma isoforms, with 30-fold less inhibition of PI3K beta relative to alpha (Ki = 0.29nM)(4).117
In taselisib early clinical development, anti-tumor activity was observed in patients with 118
ER-positive breast cancer, with proportionately more responses in PIK3CA-mutant 119
compared with PIK3CA wild-type tumors, consistent with preclinical data(5). This was true 120
both for taselisib as a single agent, and also for taselisib in combination with other anti-121
oestrogens fulvestrant and letrozole(6,7).122
123
Tamoxifen is well established endocrine therapy frequently used for the treatment of ER-124
positive breast cancer, increasingly in patients who have failed prior endocrine therapies 125
including aromatase inhibitors and/or fulvestrant. To overcome endocrine resistance, 126
CDK4/6 inhibitors have shown to be of added value(8), and are increasingly being utilized 127
in the first or second-line setting. However not all patients derive benefit from a 128
combination with CDK4/6 inhibitors. Inhibition of the PI3K pathway in combination with 129
tamoxifen may be beneficial for a significant proportion of ER-positive patients, most likely 130
in the second- or third-line setting.  131
132
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We undertook a phase 1b trial to establish the safety, tolerability, and recommended 133
phase 2 dose (RP2D) of taselisib in combination with tamoxifen, for patients with hormone 134
receptor (HR)-positive metastatic breast cancer with progression after prior endocrine 135
therapy. Secondary and exploratory objectives included assessment of pharmacokinetics 136
(PK) and (preliminary) anti-tumor efficacy. Correlative translational studies were performed 137
to identify biomarkers with potential clinical utility, including intensive plasma sampling for 138
circulating tumor (ct)DNA analysis using next generation tagged amplicon sequencing.139
ctDNA monitoring in early phase clinical trials may have value in drug development(9) for140
the assessment of biomarkers which can: predict response to therapy(10); provide an 141
early indication of treatment response(11); and shed light on potential mechanisms of 142
acquired drug resistance(12).143
144
PATIENTS AND METHODS 145
146
Patients147
This phase 1b, multi-centre, dose-escalation study was conducted in Amsterdam,148
Barcelona and Cambridge, UK. The study was conducted in accordance with Good 149
Clinical Practice and the Declaration of Helsinki and was approved by regulatory 150
authorities, ethics committees and institutional review boards at each site. All patients had 151
HR-positive breast cancer and provided written informed consent before taking part. Other 152
key inclusion criteria: measurable or non-measurable disease according to Response 153
Evaluation Criteria In Solid Tumors (RECIST) version 1.1; age 18 years; life expectancy 154
 12 weeks; fasting glucose  120mg/dL and HbA1c below the upper limit of normal (ULN). 155
Key exclusion criteria: more than 5 prior chemotherapeutic regimens for metastatic breast 156
cancer; presence of untreated, symptomatic or progressive brain metastases; diabetes 157
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mellitus requiring anti-hyperglycemic medication; history of thrombo-embolic or 158
inflammatory bowel disease. 159
160
161
Study Design and Drug Administration 162
The phase 1b part of the POSEIDON trial reported here used a rolling 6 design to test 3 163
doses/schedules of taselisib tablets in combination with 20mg tamoxifen daily (QD).164
Cohort 1 tested tamoxifen plus 2mg taselisib QD in a 21 day on / 7 day off intermittent 165
schedule; Cohort 2 tested tamoxifen plus 4mg taselisib QD in a 21 day on / 7 day off166
intermittent schedule; and Cohort 3 tested tamoxifen plus 4mg taselisib QD in a 28 day167
continuous schedule. Planned cohort expansions were undertaken in cohorts 2 and 3 to 168
gain additional preliminary data regarding safety, tolerability and efficacy. On cycle 1 day 1, 169
only taselisib was administered for single agent PK studies. Tamoxifen was administered 170
in combination with taselisib from cycle 1 day 2 onwards.171
172
Safety & Dose Intensity 173
Data on Adverse Events (AEs) was collected according to the NCI Common Terminology 174
Criteria for Adverse Events (CTCAE) version 4.03. All AEs were collected regardless of 175
causality until 30-days after the last study drug administration. Dose-Limiting Toxicities 176
(DLTs) were those treatment-emergent AEs occurring during cycle 1 (days 1-28) which 177
warranted a dose-reduction or which were grade 3 with exceptions listed in178
Supplementary Methods [SM]. Relative dose intensity of both taselisib and tamoxifen was 179
defined as the actual received dose intensity divided by the intended dose intensity. 180
181
Plasma Pharmacokinetic and Circulating Tumor (ct)DNA Studies182
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Details of plasma taselisib(13) and tamoxifen(14) pharmacokinetic assays, and ctDNA 183





Tumor response to treatment was evaluated clinically and also by CT scan assessments 189
every 8 weeks (2 cycles of treatment), with confirmation of objective responses performed 190
≥ 4 weeks later. Time to progression (TTP) was calculated from start of treatment until 191





Baseline Patient Demographics and Disease Characteristics 197
From November 2014 to January 2016, 30 patients were enrolled. The cut-off for data 198
analysis was 8 February 2018. Median treatment duration was 4 months (range 1-17). 199
Patients had a median of 2 lines of prior endocrine therapy (range 0-3) and 2 lines of prior 200
cytotoxic chemotherapy (range 0-7) for metastatic disease. Overall 25 out of 30 patients 201
(83%) had received a prior aromatase inhibitor for the treatment of metastatic disease, and 202
6/30 (20%) prior fulvestrant (Table 1). 203
204
Safety and Tolerability 205
No DLTs were observed. However, shortly after finishing the DLT window, one patient in 206
cohort 1 developed diarrhea grade 3 due to colitis, therefore the cohort was expanded. As 207
predefined, cohorts 2 and 3 were expanded to confirm safety of these dose levels. 208
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Following independent data monitoring committee review, the RP2D of taselisib in 209
combination with tamoxifen was set at 4mg in a continuous schedule.  210
211
The most common treatment-emergent AEs of any grade were elevated liver enzymes (13212
out of 30 patients [43%]), diarrhea (43%), anemia (40%) and oral mucositis (33%, Table 2). 213
The majority of these AEs first occurred during the DLT window, persisted during study 214
treatment, but reversed after treatment discontinuation. AEs of special interest occurred in 215
6 patients (20%): 3 patients had diarrhea grade 3 due to colitis, 2 patients had rash grade 216
3 and 1 patient developed pneumonitis grade 4. After withholding the study drugs, and217
treatment with high dose corticosteroids, all recovered to ≤ grade 1. 218
219
Pharmacokinetics220
The concentration-time curves for taselisib in combination with tamoxifen at cycle 1 day 15 221
are shown in [S1]. Samples from POSEIDON trial are displayed as individual data points 222
against the backdrop of a population PK model from the broader taselisib clinical 223
development programme provided by Genentech. At the taselisib 4mg daily dose level, 224
combining patients on intermittent and continuous schedules, the cycle 1 day 15 median 225
Cmax for taselisib in combination with tamoxifen was 68.7 ng/mL and median AUC 1070 226
ng.h/mL, compared with an expected median Cmax of 59.2 ng/mL (range 33.6-111) and 227
median AUC 1190 ng.h/mL (range 630-2273) from the single agent taselisib population PK 228
model. Endoxifen levels are shown in [S2]. 229
230
Anti-tumor activity and PIK3CA mutational status 231
Six patients had a confirmed RECIST partial response, yielding an objective response rate 232
(ORR) of 24% in the RECIST-measurable group (n=25), or 20% in the overall intention-to-233
treat population (n=30). Best responses according are shown as a waterfall plot in Figure 1,234
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alongside an oncoprint plot showing key gene mutations in baseline plasma or tumor 235
tissue samples. Median TTP for the whole population was 4 months (inter-quartile range 2-236
8), and 8 months for patients achieving a RECIST partial response. The timecourse of 237
responses to treatment are also visualised on a spider plot (Figure 2) and a swimmers plot 238
[S3]. 12 out of 30 patients had disease control for 6 months or more, thus a 6-month 239
clinical benefit rate (CBR) of 40%.  240
241
PIK3CA mutation testing was done for all patients on baseline tumor tissue and on plasma 242
ctDNA samples. PIK3CA mutations were found in 8/30 (27%) of patients (see Oncoprint 243
Figure 1 and mutation lollipop diagram [S4]). In this group of 8 patients with PIK3CA244
mutant tumors, 3 patients had a PR, and the other 5 stable disease as their best response. 245
There was no statistically significant difference for PIK3CA mutant (exon 9, exon 20 or 246
both) vs. wild-type subgroups for either ORR (38% v. 14%) or TTP (153 v. 113 days, 247
respectively).248
249
Circulating tumor (ct)DNA correlative studies 250
All patients had serial plasma sampling for ctDNA correlative studies. Here we describe 251
four patients in whom ctDNA results illustrate molecular correlates with treatment response 252
(Figure 3). ctDNA was not detected in all patients, and our data set was not powered to 253
detect overall correlations in the whole patient group. 254
255
In the first case, the patient had previously received weekly paclitaxel and anastrozole as 256
treatment for her PIK3CA mutant breast cancer metastatic to bone, lung, and 257
subcutaneous tissues, and was treated with tamoxifen plus taselisib in the 4mg QD 258
continuous schedule. A rapid fall in plasma ctDNA PIK3CAH1047R fraction was observed 259
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just 1 week after starting therapy, 7 weeks before her first scheduled CT scan to assess 260
treatment response.  261
262
In the second case, the patient had previously received epirubicin, exemestane and 263
capecitabine as treatment for her PIK3CA mutant breast cancer metastatic to liver and 264
bone and was treated with tamoxifen plus taselisib in the 4mg QD continuous schedule. 265
She did not respond to treatment and an increase in plasma ctDNA PIK3CAH1047R fraction266
was seen on cycle 1 day 15, six weeks before her end of cycle 2 restaging CT scan.267
268
In the third case, the patient had previously received paclitaxel, anastrozole, everolimus-269
exemestane, capecitabine, vinorelbine-docetaxel and letrozole to treat her PIK3CA wild-270
type breast cancer metastatic to liver and bones and was treated in the tamoxifen plus 271
taselisib 4mg QD 21/7 intermittent cohort. She did not respond to treatment and increases 272
in plasma ctDNA levels were found for GATA3 and KRAS mutations two weeks ahead of 273
cycle 2 CT scan.  274
275
In the fourth case, the patient had previously received paclitaxel, letrozole, docetaxel, 276
capecitabine, exemestane and eribulin to treat her PIK3CA wild-type breast cancer 277
metastatic to liver and bones and was treated in the tamoxifen plus taselisib 4mg QD278
continuous cohort. She did not respond to treatment and increases in plasma ctDNA levels 279
were found for ERBB2 and CDH1 mutations 34 and 27 days respectively before she came 280
off trial with disease progression. 281
282
DISCUSSION 283
Taselisib in combination with tamoxifen is generally well tolerated, with a side effect profile 284
that was manageable, and consistent with taselisib given as a single agent and in 285
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combination with other endocrine agents. In keeping with other PI3K inhibitors, the 286
commonest side effects were diarrhea, anemia, nausea, mucositis and hyperglycemia.287
Three out of 30 patients had grade 3 colitis, one patient was found to have grade 4 288
pneumonitis, all of which were reversible. The RP2D of taselisib in combination with 289
tamoxifen was determined to be 4mg on a daily continuous schedule.   290
291
Tamoxifen is a pro-drug that is converted to its active metabolites by cytochrome (CYP) 292
P450 enzymes including CYP2D6, CYP3A4, CYP2B6, and CYP2C19. Taselisib is a weak 293
inhibitor of CYP3A4 and does not inhibit any other CYPs in vitro, and did not alter the PK 294
of midazolam, a CYP3A4 substrate, in the first-in-man study of taselisib (PMT4979g).295
Therefore, no change in taselisib PK was expected when given in combination with 296
tamoxifen.  Indeed, the observed taselisib concentrations at day 15 of cycle 1 were in the 297
same range as those of a previously treated single agent taselisib cohort. Also, cycle 2 day 298
1 Z-endoxifen levels were on average above the laboratory threshold of 5.9 ng/mL(16) in299
all dose levels.300
301
Preliminary evidence of anti-tumor activity was observed, with confirmed partial responses 302
seen in 6/25 patients with RECIST-measurable disease (ORR 24%). Responses were 303
seen in patients with PIK3CAH1047R mutant, PIK3CAE545K mutant and PIK3CAWT tumors.  304
305
A strong rationale exists to explore the combination of PI3K inhibitors with endocrine 306
therapy for the treatment of ER+ breast cancer. The combination of tamoxifen with 307
everolimus improved the median time to progression from 4.5 to 8.6 months in the 308
TAMRAD trial (1), and it is an important research question to test whether or not isoform-309
selective PI3K inhibitors have therapeutic advantages over TORC inhibitors in this setting. 310
In addition to the POSEIDON trial combination with tamoxifen, taselisib is given in clinical 311
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trials together with fulvestrant (NCT02340221)(17) and letrozole (NCT02273973)(7).312
Although PIK3CA mutations have been implicated in primary endocrine resistance and 313
their prevalence is relatively high (20-25% in ductal breast cancer and 40% in lobular 314
breast cancer), results are conflicting(18,19) and the outcome might depend on the 315
specific mutation that is studied(20).316
317
In the SANDPIPER randomised phase 3 trial (NCT02340221)(17), patients with or without 318
a PIK3CA mutation were randomised between taselisib plus fulvestrant and placebo plus 319
fulvestrant. Taselisib dose and schedule were the same as recommended for phase 2 of 320
the POSEIDON study (ie. taselisib 4mg daily continuous). Median PFS with taselisib plus 321
fulvestrant in patients with a PIK3CA mutation was significantly longer (7.4 months) than 322
with placebo plus fulvestrant (5.4 months; HR 0.70). No significant PFS difference was 323
observed in patients who had a PIK3CA wildtype tumor (median PFS 5.6 months vs 4.0 324
months). However, information about a test for interaction is lacking. Adverse events grade 325
3 or higher were observed in almost half of the patients. The toxicity profile seen in 326
POSEIDON is consistent to that reported in previous trials testing taselisib plus endocrine 327
therapy in the metastatic setting. Additionally, in the SOLAR-1 randomised phase 3 trial 328
(NCT02437318)(21) patients with HR-positive, HER2-negative advanced breast cancer 329
were randomised to receive fulvestrant plus the alpha-isoform-selective PI3K inhibitor 330
alpelisib, or placebo. The addition of alpelisib to fulvestrant improved PFS in patients with 331
PIK3CA mutations but not PIK3CA wild-type patients (median PFS 20 vs. 11 months). 332
333
Despite these encouraging results, PIK3CA mutational status may not on its own be 334
sufficient to optimally identify which ER-positive breast cancer patients will benefit most 335
from the addition of a PI3K inhibitor to endocrine therapy. Individual patients with PIK3CA336
wild-type tumors can respond, and some patients with PIK3CA mutant tumors do not.337
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Further studies are required to identify the optimal biomarker profile for PI3K combination 338
therapy, and how best to use the results of real-time plasma ctDNA monitoring for 339
the management of individual patients. These questions are being addressed in the 340
randomised phase 2 part of POSEIDON which is ongoing. 341
342
To conclude, the RP2D of taselisib in combination with tamoxifen 20mg daily is 4mg QD in 343
a continuous schedule. Phase 2 of POSEIDON (NCT02301988) is currently recruiting and 344
randomises patients (N=280 in total) to receive tamoxifen 20mg daily with either taselisib 345
4mg or placebo once daily; including a specific focus on patients with lobular breast 346
cancer (N=110); and a major translational effort to identify predictive biomarkers to help 347
select which patients are most likely to benefit from the addition of a PI3K inhibitor to their 348
endocrine therapy. 349
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TABLE & FIGURE HEADERS 444
445
Table 1. Patient baseline characteristics. 446
447
Table 2. Most frequently observed treatment-emergent adverse events.  448
449
Figure 1. Anti-tumor activity and pre-treatment tumor genetics (all patients, N=30).450
a) Waterfall plot showing best treatment response for all 30 patients – 25 with RECIST-451
measurable disease and 5 with non-measurable disease (the latter marked by an 452
asterisk*). Best RECIST response and time on treatment in months are indicated for each 453
patient. PR - partial response, SD - stable disease, PD - progressive disease). 454
b) Oncoprint plot showing pre-treatment mutation status of PIK3CA, PIK3R, PTEN, 455
MAP3K1 and TP53 genes. In each square, detection of a mutation in the tissue (primary or 456
metastatic) is shown on the left side, while detection on plasma (at baseline) is shown on 457
the right. Cases where tissue was not available are indicated in dark grey; for all the others, 458
both tissue and plasma were tested. The black outline indicates that the mutation is 459
present in Cosmic database. The white star indicates mutations in tissue and plasma are 460
not in the same position. Numbers on the top indicate the exon of PIK3CA mutations (9 or 461
20); T–tumor, P–plasma. 462
463
Figure 2. Spider plot showing change in tumor size over time for individual patients 464
with RECIST-measurable disease (N=25). 465
466
467
Figure 3. Circulating tumor (ct)DNA correlative case studies. 468
In four individual patients each having different clinical outcomes, the variant allele fraction 469
is shown over time for gene mutations in plasma whilst on study treatment.  470
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471
S1. Supplementary Figure 1. Taselisib pharmacokinetics in combination with 472
tamoxifen.473
474
S2. Supplementary Figure 2. Pharmacokinetics: Z-endoxifen levels per taselisib 475
dose level.476
477
S3. Supplementary Figure 3. Time to progression per patient in a swimmers plot (all 478
patients, N=30).479
480
S4. Supplementary Figure 4. PIK3CA mutations detected at baseline (in samples 481
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